LAMICTAL XR (lamotrigine) by GSK is organic cation transporter 2 inhibitors [moa]. Approved for anti-epileptic agent [epc]. First approved in 2009.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
LAMICTAL XR is an extended-release oral tablet formulation of lamotrigine, an anti-epileptic agent approved in 2009. It treats seizure disorders by inhibiting organic cation transporter 2, reducing abnormal neuronal firing. The product serves patients requiring once-daily seizure management with sustained drug exposure.
Product faces imminent loss of exclusivity in 2.6 years; brand teams should expect declining market share and consolidation of commercial resources.
Organic Cation Transporter 2 Inhibitors
Anti-epileptic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
Worked on LAMICTAL XR at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
LAMICTAL XR offers limited career upside due to imminent loss of exclusivity and minimal commercial infrastructure. Roles on this team will focus on defensive market management, generic transition planning, and legacy brand maintenance rather than growth-oriented innovation.